Polyrizon Signs Non– Binding LOI to Expand its Innovative Intranasal Drug Delivery Platform for Psychedelic-Based Treatments
“Our proprietary intranasal platform has the potential to enhance drug delivery bioavailability. We believe that intranasal delivery has the potential to improve patient outcomes by providing a ...
Polyrizon Launches Preclinical Studies for Intranasal Naloxone to Combat Opioid Overdose Using Cutting-Edge Platform
Raanana, Israel, March 13, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative ...
Morningstar2d
Polyrizon Signs Non– Binding LOI to Expand its Innovative Intranasal Drug Delivery Platform for Psychedelic-Based Treatments
Raanana, Israel, March 14, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development stage biotech company specializing in the development of ...
Polyrizon Ltd.: Polyrizon Signs Non- Binding LOI to Expand its Innovative Intranasal Drug Delivery Platform for Psychedelic-Based Treatments
Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal ...
Nasdaq1d
Polyrizon Ltd. Signs Letter of Intent to Develop Intranasal Formulation for Psychedelic-Based Therapeutics
Polyrizon Ltd. has announced a non-binding Letter of Intent with a biotech company focused on psychedelic-derived therapeutics to develop a new intranasal formulation for treatment applications ...
Investing2d
Polyrizon partners for psychedelic treatment delivery
RAANANA, Israel - Polyrizon Ltd. (NASDAQ:PLRZ), a development-stage biotech company with a market capitalization of $2.85 million, announced today its collaboration with an unnamed biotech company ...
Nasdaq2d
Polyrizon Ltd. Initiates Preclinical Studies for Intranasal Naloxone to Enhance Opioid Overdose Treatment
Polyrizon Ltd., a biotech company focused on developing intranasal hydrogels, has started preclinical studies for an intranasal formulation of Naloxone, intended to treat opioid overdoses.
Polyrizon Ltd.: Polyrizon Launches Preclinical Studies for Intranasal Naloxone to Combat Opioid Overdose Using Cutting-Edge Platform
Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal ...
The Bakersfield Californian1d
Polyrizon Signs Non– Binding LOI to Expand its Innovative Intranasal Drug Delivery Platform for ...
Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announced ...
Investing3d
Polyrizon advances naloxone intranasal delivery studies
RAANANA, Israel - Polyrizon Ltd. (NASDAQ:PLRZ), a biotech firm in the development stage with a market capitalization of $2.95 million, is progressing in its preclinical studies for an intranasal ...
Yahoo Finance6d
Polyrizon Initiates Preclinical Studies for Intranasal Naloxone Targeting Opioid Overdose Based on Its Innovative T&T Platform
Raanana, Israel, March 10, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative ...